NasdaqGM - Delayed Quote USD

Denali Capital Acquisition Corp. (DECA)

Compare
11.51 0.00 (0.00%)
At close: October 4 at 4:00 PM EDT
Loading Chart for DECA
DELL
  • Previous Close 11.51
  • Open 11.51
  • Bid --
  • Ask --
  • Day's Range 11.51 - 11.51
  • 52 Week Range 4.05 - 14.10
  • Volume 7
  • Avg. Volume 1,725
  • Market Cap (intraday) 32.393M
  • Beta (5Y Monthly) 0.32
  • PE Ratio (TTM) 30.29
  • EPS (TTM) 0.38
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Denali Capital Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. It intends to complete a business combination with companies primarily operating in the technology, consumer services, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: DECA

View More
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination

Top Midday Gainers

Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
Denali Capital Acquisition Corp. Announces Postponement of Extraordinary General Meeting From Thursday, January 4, 2024 to Tuesday, January 9, 2024

Denali Capital Acquisition Corp. Announces Postponement of Extraordinary General Meeting From Thursday, January 4, 2024 to Tuesday, January 9, 2024
View More

Performance Overview: DECA

Trailing total returns as of 10/16/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

DECA
13.18%
S&P 500
22.49%

1-Year Return

DECA
5.21%
S&P 500
35.00%

3-Year Return

DECA
15.68%
S&P 500
40.42%

5-Year Return

DECA
15.68%
S&P 500
40.42%

Compare To: DECA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: DECA

View More

Valuation Measures

Annual
As of 10/15/2024

  • Market Cap

    32.39M

  • Enterprise Value

    34.79M

  • Trailing P/E

    30.45

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.75

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    17.63

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -1.09%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    1.9M

  • Diluted EPS (ttm)

    0.38

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.5k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -235.21k

View More

Company Insights: DECA

People Also Watch